Our overall ambition is to develop neuroprotective and potentially neurorestorative treatment for neurodegenerative diseases which is – as yet – unavailable.

With respect to anti-viral strategies, Genecode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts.
History

Genecode history starts in 1993 when it was founded with initial name Baltic Technology Development Ltd (BTD) as an Estonian-Finnish private science-development company. The founders were Dr. Mehis Pilv and Dr. Harald Velner from Estonia and Mr. Hans Rehnstöm from Finland.

From 2006 the shareholders are Dr. Mehis Pilv, Dr. Mati Karelson and US company Baltic Technology LLC (represented by Thomas Bjoern Waldin).

At 2010 the company was renamed to Genecode Ltd.

Strategy

Neurodegenerative diseases - Genecode applies proprietary drug design technologies for innovative target mechanisms. This enables the synthesis and development of novel small-molecule drug candidates which validates the target biology towards its proposed indications, such as Parkinson`s disease, spinal cord injury, Huntington`s disease, motor neuronal disease, multiple sclerosis, Alzheimer`s disease and pain.

Anti-viral strategies - Genecode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. By disrupting the viral lifecycle Genecode`s approach is delivering promising treatment options for Hepatitis C, HIV and Chikungunya virus.

Drug design technologies - All proprietary methods for novel drug design technologies and drug candidates developed by Genecode are aimed to function as disease modifiers and ultimately as cures, not as disease symptom treatments.
Platform Technology Patents

Both the identification and optimization of small molecule methods towards growth factor receptors and the improved antisense technologies have been globally patented and serve Genecode`s new Technological Platforms of drug design.


“METHODS OF FACILITATING NEURAL CELL SURVIVAL USING GDNF FAMILY LIGAND (GFL) MIMETICS OR RET SIGNALING PATHWAY ACTIVATORS”

The diseases, targeted by this GENECODE Patent protected inventions are listed in the background information of the Patent, section (0014):

The disorders targeted by the present invention include Alzheimer`s disease, Huntington`s disease, amyotrophic lateral sclerosis, Rett syndrome, epilepsy, Parkinson`s disease, spinal cord injury, stroke, hypoxia, ischemia, brain injury, diabetic neuropathy, peripheral neuropathy, nerve transplantation complications, motor neuron disease, multiple sclerosis, HIV dementia, peripheral nerve injury, hearing loss, depression, obesity, metabolic syndrome, pain, cancer, and other conditions involving degeneration or dysfunction of cells expressing GFRα/RET.


“ANTISENSE AGENTS COMBINING STRONGLY BOUNDING BASE-MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE”

The diseases, targeted by this GENECODE Patent protected inventions are listed in the background information of the Patent:

The specific binding of antisense oligonucleotides to the DNA or RNA targets can inactivate the replication, transcription, or translation of nucleic acids, thereby providing mechanism for controlling diseases such as cancer and viral infection. The binding of antisense oligonucleotide to a target can be thus used to alter gene expression, in variety of circumstances, e.g. to interfer with viral life cycles, or the growth of cancerous cells.
Company Structure

Genecode Ltd is organized as a Genecode Group of companies. Genecode Ltd is a mother company and has 3 specialized daughter companies – Neuroncode Ltd, Olicode Ltd and Cerecode Ltd.

All activities and IPR are in Genecode Ltd and the specialized daughter companies, in which the majority shareholder is Genecode Ltd, have been formed only as a holding companies of the shares of the new partners.

Partners & Shareholders

Genecode scientific partners are all internationally well known leading scientists in various areas of biomedical sciences.

Genecode scientific partners have published more then 600 publications with more then 30 000 citations and are inventors or co-inventors of more than 50 patent families and patents.

Partnering Opportunities

Contact person:
Mehis Pilv
mehis.pilv@gmail.com

GENECODE LTD, WTC TALLINN
Ahtri street 8, 10151 Tallinn, ESTONIA
www.genecode.com